Open Angle Glaucoma News Today

Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six months, with...

Glaukos Corporation , an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today...

Did you know glaucoma silently steals sight? Uncover shocking stats and ways to protect your vision! Discover more now.

Glaucoma Awareness Month: Several factors increase the risk of developing glaucoma. Regular eye check-ups, especially for those with risk factors, are paramount, as is awareness because often, it goes undetected in its initial stages. 

Glaucoma is a disorder of the eye that gradually steals sight without warning. It is the leading cause of blindness in the United States.

Volume and frequency of alcohol consumption were associated with a greater risk of visual impairment and blindness among patients with newly diagnosed OAG.

What Is Glaucoma? Types, Symptoms And Causes

Retrospective Clinical Data from Seven US Sites Published in Clinical Ophthalmology Sustained and clinically meaningful IOP reductions observed at 12 months persisted through 24 monthsSustained and... | May 23, 2023

Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today... | May 1, 2023

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programmin...